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Abstract
Objective
To compare the diagnostic accuracy of the McDonald 2017 vs the McDonald 2010 criteria to
predict a second attack of MS (clinically deﬁnite MS [CDMS]) at the ﬁrst attack of acquired
demyelinating syndromes (ADS).
Methods
One hundred sixty-four children (aged <18 years) with an incident attack of ADS were included
in a prospective multicenter study between June 2006 and December 2016. Brain (and spinal if
available) MRI was performed ≤3 months after symptom onset. Sensitivity, speciﬁcity, positive
predictive value, negative predictive value, and accuracy were compared at baseline between the
2010 and 2017 criteria.
Results
Among the 164 patients, 110 patients (67%) presented without encephalopathy (ADS–, female
63%; median age 14.8 years, IQR 11.3–16.1years) and 54 (33%) with encephalopathy (acute
disseminated encephalomyelitis [ADEM], female 52%; median age 4.0 years, IQR 2.6–6.1
years). Of the 110 ADS– patients, 52 (47%) were diagnosed with CDMS within a median
follow-up of 4.5 years (IQR 2.6–6.7 years). The sensitivity was higher for the 2017 criteria than
for the 2010 criteria (83%; 95%CI 67–92, vs 49%; 95%CI 33–65; p < 0.001), but the speciﬁcity
was lower (73%; 95% CI 59–84 vs 87%; 95% CI 74–94, p = 0.02). At baseline, 48 patients
fulﬁlled the 2017 criteria compared with 27 patients when using the 2010 criteria. The results
for children aged <12 years without encephalopathy were similar. In patients with ADEM, 8%
fulﬁlled the 2010 criteria and 10% the 2017 criteria at baseline but no patient fulﬁlled the criteria
for CDMS.
Conclusions
TheMcDonald 2017 criteria are more sensitive than the McDonald 2010 criteria for predicting
CDMS at baseline. These criteria can also be applied in children aged <12 years without
encephalopathy but not in children with ADEM.
Classification of evidence
This study provides Class II evidence that in children with ADS, the 2017McDonald criteria are
more sensitive but less speciﬁc than the 2010 McDonald criteria for predicting CDMS.
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MS is a chronic demyelinating disorder of the CNS.1 Up to
10% of all patients with MS have their ﬁrst symptoms before
age 18 years.2,3 Recently, the international panel on diagnosis
of MS proposed theMcDonald 2017 criteria by reviewing and
revising the previous 2010 McDonald criteria.4,5 These re-
vised criteria include modiﬁcations to facilitate earlier MS
diagnosis while attempting to preserve the diagnostic accu-
racy of the criteria.5 Important modiﬁcations included rein-
troducing CSF oligoclonal bands (OCBs) into the criteria as
a substitute for dissemination in time (DIT) and allowing
symptomatic lesions to contribute to dissemination in space
(DIS) and DIT. Furthermore, cortical lesions have been
combined with the juxtacortical lesion component to dem-
onstrate DIS.
The applicability of the adult McDonald 2010 criteria in
children was supported by several studies.6–12 These criteria
were implemented in the revised 2012 diagnostic criteria for
children with acquired demyelinating syndromes (ADS)
proposed by the International Pediatric MS Study Group
(IPMSSG).13 ADS encompass the ﬁrst attack of demyelin-
ation in the CNS.13,14 According to the IPMSSG criteria, MS
diagnosis based on the ﬁrst baseline MRI in children with
a ﬁrst attack should be performed with caution for children
aged <12 years and patients presenting with acute dissemi-
nated encephalomyelitis (ADEM) because of a lower spec-
iﬁcity and sensitivity of the McDonald 2010 criteria in these
groups.13
A Canadian study reported that the revised McDonald 2017
criteria apply well in children with a ﬁrst attack of ADS across
the age span.15 Validation of these criteria in diﬀerent study
populations is imperative because of the long-term adminis-
tration of disease-modifying treatment (DMT) after MS di-
agnosis. Overtreatment in patientsmust be prevented, as well as
undertreatment, because of delayed diagnosis. Early and accu-
rate identiﬁcation of patients with MS is therefore essential.
We aimed at evaluating the diagnostic accuracy of the revised
2017 MS criteria in children with ADS at the time of the ﬁrst
presentation. Extra attention is paid to children younger than
age of 12 years and to patients presenting with ADEM.
Methods
Patients and design
Children younger than 18 years with a ﬁrst attack of de-
myelination were consecutively included in the nationwide,
multicenter, and prospective study for children with ADS
between June 2006 and December 2016 (PROUD-kids
study).16,17 Patients were assessed at baseline and were pro-
spectively followed up. MRI was performed within 3 months
after symptom onset as part of a routine diagnostic process to
rule out alternative diagnoses. Patients with alternative non-
demyelinating disorders were excluded from our study. All
patients had a follow-up (FU) duration of at least 1 year
because the interval between the ﬁrst and second attacks in
pediatric MS is typically less than 1 year.18–21
Patients were included for analysis when presenting with
ADS without (ADS–) and with encephalopathy (ADEM).13
Patients with neuromyelitis optica spectrum disorders or with
relapsing disease other than MS were excluded from analyses
(e.g., patients presenting with relapsing anti–MOG antibody
related disorders) because there is emerging evidence that
these patients have a distinct clinical phenotype.22,23
Standard protocol approvals and
patient consents
The PROUD-kids study protocol was approved by the Ethics
Committee Erasmus MC, Rotterdam, and by the other par-
ticipating centers in the Netherlands. Written informed con-
sent was obtained from all patients and/or their families.
Definitions
ADS in children encompass the ﬁrst attack of demyelination
in the CNS, including patients presenting with (ADS+) and
without encephalopathy (ADS–). ADEM was deﬁned as
a polyfocal onset with encephalopathy (ADS+).13 Clinically
deﬁnite MS (CDMS) was deﬁned as a second attack of MS,
with 2 nonencephalopathic conﬁrmed attacks with clinical
evidence of 2 separate lesions.13 ADS– patients who remained
monophasic were deﬁned as monophasic ADS–.13 Patients
were reassessed annually. The patients were instructed to
contact the outpatient clinic if new symptoms occurred to be
clinically assessed. A relapse was deﬁned as new neurologic
deﬁcits or subacute worsening of existing symptoms after 30
days of improvement or stable disease, without evidence of an
alternative diagnosis.24
Procedures
Brain and spine MRI scans were performed at 1.5 Tesla
scanners. Available T1-, axial T2-, axial and/or sagittal ﬂuid-
attenuated inversion recovery (FLAIR)-, and T1-weighted
images with gadolinium administration were evaluated cen-
trally. TheMRI scan closest to the date of symptom onset was
evaluated as the baseline scan.
Glossary
ADEM = acute disseminated encephalomyelitis; ADS = acquired demyelinating syndrome; CDMS = clinically deﬁnite MS;
DIS = dissemination in space; DIT = dissemination in time; DMT = disease modifying treatment; FLAIR = ﬂuid-attenuated
inversion recovery; FU = follow-up; HR = hazard ratio; IPMSSG = International Pediatric MS Study Group; NPV = negative
predictive value; OCB = oligoclonal band; PPV = positive predictive value.
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For DIS, all baseline MRI scans were scored using the
McDonald 2010 criteria and the modiﬁed components as
described in the revised McDonald 2017 criteria for the ﬁrst
MRI scan (table 1). MRI techniques, such as double in-
version recovery, that are required to reliably demonstrate
cortical lesions were not part of the routine MRI protocol.
Therefore, the cortical lesion component was not taken into
account in our analyses. If a spinal MRI was performed
within 30 days after or before brain MRI, this scan was taken
into account in scoring the DIS components. For DIT, all
MRI scans with post-gadolinium T1 images were used; or
scans that did not have gadolinium administered, but did
not show any FLAIR/T2 hyperintense lesions either. CSF
analyses for OCBs were performed in local laboratories
using isoelectric focusing.25 OCB status was considered
positive if there were ≥2 unique bands in CSF compared
with serum.
Rationale
We set out to analyze our data in amanner that is representative
for clinical practice. As acknowledged by the International
Panel on Diagnosis of MS, spinal cord MRI and/or lumbar
puncture was not performed in every case depending on clinical
presentation and was left to the decision of the local treating
physician.5 We did not exclude patients without a spinal cord
MRI or lumbar puncture because this would probably in-
troduce selection bias in our study.
DIS was based on 3 parameters (periventricular, juxtacortical,
and infratentorial) or 4 including spinal localization if a spinal
MRI was performed. We allowed OCB status to contribute to
the fulﬁllment of DIT 2017 in patients with no gadolinium
enhancement.
Statistical analyses
For statistical analyses, we used SPSS software, version 24.0
(SPSS Inc.) and GraphPad Prism5. CDMS diagnosis was
used as an endpoint for all following analyses. For group
comparisons, the χ2 test and Fisher exact test were used for
categorical data. The Mann-Whitney U test was used for
continuous data.
Diagnostic performance and accuracy
Patients fulﬁlling the diagnostic criteria at the time of the ﬁrst
attack with a subsequent diagnosis of CDMS during FUwere
considered true positives. False positives did fulﬁll the di-
agnostic criteria for MS at baseline MRI but were not di-
agnosed with CDMS during FU. Patients who did not fulﬁll
the diagnostic criteria at baseline MRI and who were not
diagnosed with CDMS during FU were considered true
negatives. False negatives were patients who did not fulﬁll
the diagnostic criteria on baseline MRI but were diagnosed
with CDMS during FU.
Sensitivity, speciﬁcity, positive predictive value (PPV), nega-
tive predictive value (NPV), and accuracy were calculated,
including a 95% CI.
Comparison between the sensitivity and speciﬁcity for the
2010 and 2017 criteria was made using the McNemar test.
Kaplan-Meier analysis was used to analyze the time to CDMS
diagnosis using the 2010 and 2017 criteria (log-rank test).
Patients who did not meet the criteria for CDMS diagnosis
during FU were considered censored observations. Cox haz-
ard regression analyses were performed to calculate hazard
ratios (HRs) for time to MS diagnosis based on the McDo-
nald 2010 criteria (applied at baseline), McDonald 2017
Table 1 Baseline MRI criteria for MS diagnosis derived from the McDonald 2010 and revised 2017 criteria
McDonald 2010 criteria for baseline MRI Revised McDonald 2017 criteria for baseline MRI
DIS DIS
At least 2 out of 4 of: At least 2 out of 4 of:
≥1 periventricular lesion ≥1 periventricular lesion
≥1 juxtacortical lesion ≥1 juxtacortical or cortical lesion
≥1 infratentorial lesion ≥1 infratentorial lesion
≥1 spinal cord lesion (symptomatic brainstem
syndromes or spinal cord lesions are excluded)
≥1 spinal cord lesion (asymptomatic and symptomatic brainstem syndromes or spinal
cord lesions are included)
McDonald 2010 criteria for baseline MRI Revised McDonald 2017 criteria for baseline MRI
DIT DIT
Simultaneous presence of asymptomatic
gadolinium-enhancing lesions
At least 1:
Simultaneous presence of asymptomatic or symptomatic gadolinium-enhancing lesions
Presence of unique CSF oligoclonal bands compared with serum as a substitute for DIT
Abbreviations: DIS = dissemination in space; DIT = dissemination in time.
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criteria (applied at baseline), and CDMS diagnosis. pValues <
0.05 were considered statistically signiﬁcant.
Data availability statement
The raw data used in this article could be shared in an ano-
nymized format by request from a qualiﬁed investigator.
Results
Patient characteristics
The inclusion and exclusion process of eligible ADS children
is displayed in ﬁgure 1. Among the 164 included patients
with a ﬁrst demyelinating event, 54 patients (33%) pre-
sented with encephalopathy (ADS+) and were diagnosed
with ADEM. The other 110 (67%) were ADS– at the time of
inclusion. Of these, 52/110 (47%) were diagnosed with
CDMS during FU (median FU time, 4.5 years, interquartile
range (IQR) 2.6–6.6 years). The median time to CDMS
diagnosis was 10.2 months (IQR 3.8–20.7 months). None of
the patients with ADEM had a second attack within a median
FU of 5.1 years (IQR 2.7–7.8). Patient characteristics and
statistical comparisons between monophasic ADS– and
CDMS are displayed in table 2.
DIS and DIT performance on baseline MRI
All test characteristics of analyses with and without children
aged <12 years are presented in table 3.
Dissemination in space
Hundred and ten ADS– patients were included for this
analysis, of whom 52 were diagnosed with CDMS during FU
(47%). Spinal MRI was included when available. The 2010
DIS criteria were fulﬁlled in 54 patients (49%). Of these, 41
were diagnosed with CDMS (76%). Additional 16 patients
fulﬁlled the 2017 DIS criteria (n = 70, 64%), and 48 of these
70 patients were diagnosed with CDMS (69%). The 2017
DIS criteria yield an increase in sensitivity of 13% compared
with the 2010 criteria (p = 0.1) and a loss in speciﬁcity of
16% (p = 0.008).
A subanalysis evaluating the fulﬁllment of DIS in patients who
had T1 images with gadolinium administration (n = 93)
yielded no diﬀerence in the results.
Of the 110 ADS– patients, 61 patients (55%) had spinal cord
imaging, and spinal lesions were detected in 45/61 scans
(74%). In a subgroup analysis, we included only patients who
underwent a spinal scan. The test characteristics of DIS were
comparable to the results mentioned earlier.
Dissemination in time
To evaluate the DIT for both criteria, we selected ADS–
patients who had T1 images with gadolinium administration
(n = 93). Of these patients, 41 were diagnosed with CDMS
during FU (44%). The 2010 DIT criteria were fulﬁlled in
35 patients (38%). Of these, 23 were diagnosed with CDMS
(66%). Regarding the diﬀerence between the symptomatic and
asymptomatic lesions for the DIT component, we observed
that the 2017 DIT criteria (excluding OCBs) yielded 3 more
patients fulﬁlling the DIT criteria (n = 38, 41%), of whom 26/38
were diagnosed with CDMS (68%). A major increase in
patients fulﬁlling DIT with the 2017 criteria is caused by
allowing OCBs to contribute to DIT when no gadolinium
enhancement was present: an additional 20 patients fulﬁlled
2017 DIT criteria at baseline (n = 58 patients, 62%). Thirty-
seven (64%) of these 58 patients were diagnosed with CDMS.
The test characteristics for 2010 and 2017 DIT criteria, ex-
cluding OCB status, were similar. When adding OCB status,
the DIT criteria yield 27% in sensitivity (p < 0.001) but lost
17% in speciﬁcity (p = 0.004) (table 3).
McDonald 2010 vs McDonald 2017 criteria
To evaluate the McDonald 2010 and 2017 criteria, we se-
lected ADS– patients who had T1 images with gadolinium
administration (n = 93). The McDonald 2010 DIS + DIT
criteria were fulﬁlled in 27/93 patients at baseline (29%), of
whom 20 were diagnosed with CDMS (74%) after a median
FU of 4.5 years (IQR 2.6–7.1 years).
The McDonald 2017 criteria identiﬁed 21 additional patients
who fulﬁlled the criteria at baseline (n = 48, 52%) compared
with the 2010 criteria, and 34/48 patients (71%) were di-
agnosed with CDMS. The sensitivity was higher in the
McDonalds 2017 criteria (83% vs 49%; p < 0.001), and the
speciﬁcity was lower (73% vs 87%; p = 0.02) (table 3).
The 7 patients who caused the loss in speciﬁcity were iden-
tiﬁed (fulﬁlling the 2017 criteria and not the 2010 criteria at
baseline, but not having a second attack during an FU of
median 2.7 years [IQR: 1.2–6.5 years]). New lesions on
subsequent MRI were observed in 4 of these 7 patients during
FU. The other 3 patients did not undergo a second MRI.
Of the 41 patients diagnosed with CDMS, the McDonald
2010 criteria led to the identiﬁcation of 20 patients (49%) at
baseline. A second attack occurred in 17/20 patients (85%)
Figure 1 Flow chart for patient inclusion
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within 3 years of FU and in 19/20 (95%) within 5 years.
With the McDonald 2017 criteria, 34/41 (83%) patients
with CDMS were identiﬁed at baseline. At 3 and 5 years of
FU, 31/34 (91%) and 33/34 (97%) had a second attack
within 3 and 5 years.
Only 1 patient who fulﬁlled the 2010 and 2017 diagnostic
criteria at baseline did not have a second attack (CDMS)
within 5 years of FU, yet this patient showed newMRI lesions
on FU scans.
The survival curves for CDMS diagnosis, the McDonald 2010
criteria, and the revised McDonald 2017 criteria on baseline
MRI are presented in ﬁgure 2. MS diagnosis could be made
earlier in patients with ADS using the 2017 than the 2010
criteria. For both criteria, the HRs for the DIS, DIT, and full
criteria at baseline are displayed in table 4.
Contribution of symptomatic enhancing
lesions, OCBs, and spinal cord imaging
As described earlier, the McDonald 2017 criteria identiﬁed 21
additional patients (n = 48) compared with the 2010 criteria
(n = 27).
These 21 patients were identiﬁed with the contribution of 2
major changes in the criteria. First, symptomatic lesions can
be included to demonstrate DIS and DIT for the McDonald
2017 criteria. This led to 7 more MS diagnoses (n = 34) at
Table 2 Patient characteristics
ADS–(n = 110)
Monophasic
ADS– (n = 58)
CDMS
(n = 52)
ADS+
(n = 54) All (n = 164) p Valuea
Sex, female, n (%) 69 (63) 32 (55) 37 (71) 28 (52) 97 (59) 0.11
Age at onset, median (IQR), y 14.8 (11.3–16.1) 13.3 (9.1–16.0) 15.4 (13.7–16.2) 4.0 (2.6–6.1) 12.1 (5.1–15.8) <0.004
Age <12 years, n (%) 30 (27) 23 (40) 7 (14) 51 (94) 81 (49) 0.002
Presenting phenotype, n (%) 0.001
Optic neuritis 36 (33) 23 (40) 13 (25) 0 36 (22) —
Transverse myelitis 18 (16) 15 (26) 3 (6) 0 18 (11) —
Other monofocal ADS– 25 (23) 11 (19) 14 (27) 0 25 (15) —
Polyfocal ADS– 31 (28) 9 (16) 22 (42) 0 31 (19) —
Polyfocal ADS with encephalopathy (ADEM) 0 0 0 54 (100) 54 (33) —
Spinal MRI, n (%) 61 (56) 34 (59) 27 (52) 14 (26) 75 (46) 0.57
Spinal cord lesions present, n (%) 45/61 (74) 23/34 (68) 22/27 (82) 11/14 (79) 56/75 (75) 0.27
Symptomatic spinal cord lesion, n (%) 29/45 (64) 18/23 (78) 11/22 (50%) 7/11 (64%) 36/56 (64) 0.07
Gadolinium administration, n (%) 89 (81) 48 (83) 41 (79) 49 (91) 138 (84) 0.63
Gadolinium enhancement, n (%) 38/89 (43) 12/48 (25) 26/41 (63) 8/49 (16) 46/138 (33) <0.001
OCBs tested, n (%) 86/110 (78) 44/58 (76) 42/52 (81) 33/54 (61) 119 (73) 0.65
OCBs present, n (%) 54/86 (49) 17/44 (39) 37/42 (88) 1/33 (3) 55 (34) <0.001
Time to baseline MRI, median (IQR), wk 1.6 (0.6–3.4) 1.4 (0.4–3.1) 2.3 (0.8–4.7) 1.4 (0.7–2.4) 1.4 (0.6–3.1) 0.02
Time to lumbar puncture, median (IQR), wk 2.5 (0.7–9.3) 1.8 (0.4–8.4) 3.3 (1.0–10.1) 1.1 (0.4–2.4) 2.0 (0.7–6.5) 0.11
Time to CDMS, median (IQR), mo 10.2 (3.8–20.7) NA 10.2 (3.8–20.7) NA NA NA
Follow-up time, median (IQR), y 4.5 (2.6–6.7) 3.4 (2.1–5.2) 6.0 (4.2–7.8) 5.1 (2.7–7.8) 4.6 (2.6–7.1) <0.001
DMT use, n (%) 63/110 (57) 15/58 (26) 48/52 (92) 1/54 (2) 64 (39) <0.001
DMT use before CDMS diagnosis, n (%) 14/63 (22) NA 14/48 (30) NA 14 (9) NA
Presence of MOG antibodies, n (%) 5/69 (7) 5/34 (15) 0/35 (0) 16/35 (46) 21/104 (20) 0.03
Presence of AQP4 antibodies, n (%) 0/61 (0) 0/40 (0) 0/21 (0) 0/27 (0) 0/88 (0) NA
Abbreviations: ADEM = acute disseminated encephalomyelitis; ADS = acquired demyelinating syndrome; AQP4 = anti-aquaporin 4; CDMS = clinically definite
MS; DMT = disease-modifying treatment; MOG = anti–myelin oligodendrocyte glycoprotein; NA = not applicable; OCB = oligoclonal band.
Patient characteristics for patients with acquired demyelinating syndromes without encephalopathy (ADS–), CDMS, and ADEM (ADS+).
In the Dutch pediatric setting, DMTs are prescribed when the patient fulfills the criteria for MS, either clinically or radiologically.
a Comparison between monophasic ADS– and CDMS. Statistical significance p < 0.05
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Table 3 Test characteristics of the McDonald 2010 and McDonald 2017 criteria
Patients with ADS– and CDMS,
excluding ADEM
DIS 2010
(n = 110)
DIS 2017
(n = 110)
DIT 2010
(n = 93)
DIT 2017 (OCBs
excluded) (n = 93)
DIT 2017 (OCBs
included) (n = 93)
McDonald (DIS +
DIT) 2010 (n = 93)
McDonald (DIS + DIT) 2017
(OCBs excluded) (n = 93)
McDonald (DIS + DIT) 2017
(OCBs included) (n = 93)
Sensitivity % (95%CI) 79 (65–89) 92 (81–98) 56
(40–71)
63 (47–77) 90 (76–97) 49 (33–65) 61 (45–75) 83 (67–92)
Specificity % (95% CI) 78 (64–87) 62 (48–74) 77
(63–87)
77 (63–87) 60 (45–73) 87 (74–94) 83 (69–91) 73 (59–84)
PPV % (95% CI) 76 (62–86) 69 (56–79) 66
(48–80)
68 (51–82) 64 (50–76) 74 (53–88) 74 (55–87) 71 (56–83)
NPV % (95% CI) 80 (67–89) 90 (75–97) 69
(55–80)
73 (59–84) 89 (72–96) 68 (55–79) 73 (60–83) 84 (70–93)
Accuracy % (95% CI) 78 (71–86) 76 (69–84) 68
(58–77)
71 (62–80) 73 (64–82) 70 (61–79) 73 (64–82) 77 (69–86)
Patients with ADS– and CDMS <12
years (excluding ADEM)
n = 30 n = 30 n = 28 n = 28 n = 28 n = 28 n = 28 n = 28
Sensitivity % (95% CI) 86 (42–99) 100
(56–100)
71
(30–95)
71 (30–95) 100 (56–100) 57 (20–88) 71 (30–95) 100 (56–100)
Specificity % (95% CI) 87 (65–97) 78 (56–92) 90
(68–98)
90 (68–98) 81 (57–94) 95 (74–100) 95 (74–100) 91 (68–98)
PPV % (95% CI) 67 (31–91) 58 (29–84) 71
(30–95)
71 (30–95) 64 (32–88) 80 (30–99) 83 (37–99) 78 (40–96)
NPV % (95% CI) 95
(74–100)
100
(78–100)
90
(68–98)
90 (68–98) 100 (77–100) 87 (65–97) 91 (69–98) 100 (79–100)
Accuracy % (95% CI) 87 (75–99) 83 (70–96) 86
(73–99)
86 (73–99) 86 (73–99) 86 (73–99) 89 (78–100) 93 (83–100)
Abbreviations: ADEM = acute disseminated encephalomyelitis; ADS = acquired demyelinating syndrome; DIS = dissemination in space; DIT = dissemination in time; CDMS = clinically definite MS.
Test characteristics of DIS criteria, DIT criteria, full McDonald 2010, and full McDonald 2017 criteria (DIS + DIT) for CDMS diagnosis in patients without encephalopathy (ADS–). DIT and DIS + DIT: patients were included for
analysis if gadolinium was administered or when no T2 lesions were present at baseline MRI. Spinal MRI was used in the evaluation of DIS and DIS + DIT if available. Subanalyses are presented of patients including ADEM and
patients younger than 12 years (excluding ADEM).
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baseline compared with the 2010 criteria (n = 27). Of these 34
patients, 25 were diagnosed with CDMS (74%).
Second, OCBs are allowed to be taken into account when
assessing DIT. This led to the other 14 patients who fulﬁlled
the McDonald 2017 criteria at baseline (total n = 48) and
caused the major increase in the sensitivity of the criteria.
Among these 48 patients, 34 (71%) were diagnosed with
CDMS.
No additional patients fulﬁlled the McDonald 2010 criteria
depending on spinal imaging. In contrast, the presence of
a spinal cord lesion contributed to fulﬁlling the McDonald
2017 criteria at baseline in 6 patients. Three of these patients
were eventually diagnosed with CDMS. Thus, 3/41 (7%)
patients with future CDMS fulﬁlled the DIS component at
baseline by performing spinal cord imaging.
Relevant subgroup analyses
DMT use before CDMS
DMTs have the potency to postpone a second attack and could
therefore inﬂuence CDMS diagnosis. We performed a sub-
group analysis after excluding patients who received DMT
before CDMS diagnosis (exclusion n = 12). In the included
patients (n = 81), test characteristics for the full criteria (DIS +
DIT) remained comparable to the total group (includingDMT
use before CDMS) for both the 2010 (sensitivity 41% vs 49%;
speciﬁcity 87% for both selections) and 2017 criteria (sensi-
tivity 83% and speciﬁcity 73% for both selections).
Analysis in ADS– patients aged <12 years
The IPMSSG recommended that the McDonald 2010 criteria
at baseline should be used with caution in patients aged <12
years. We applied the novel 2017 criteria to the group of patients
younger than 12 years only after exclusion of ADEM cases.
Seven of 28 ADS– patients (25%) were diagnosed with
CDMS. Five patients (18%) fulﬁlled the baseline criteria for
2010, and 4 of them (80%) fulﬁlled the criteria for CDMS.
Nine patients fulﬁlled the 2017 criteria (32%), and 7 (78%)
were diagnosed with CDMS.
The test characteristics were even better in children aged <12
years than in the total group for both McDonald 2010 criteria
(sensitivity 57% vs 49%; speciﬁcity 95% vs 87%) and 2017
criteria (sensitivity 100% vs 83%; speciﬁcity 91% vs 73%).
Analysis in the ADEM subgroup
Only patients with ADEM are included in this analysis (n =
54). DIS was fulﬁlled for the 2010 criteria and 2017 criteria in
24 (44%) vs 28 (52%) patients with ADEM, respectively.
Regarding DIT, 7/49 (14%) patients with ADEM fulﬁlled the
2010 DIT criteria and 9/49 (18%) fulﬁlled the 2017 DIT
criteria, including OCB status. Of note, 4/49 (8%) patients
would have fulﬁlled the McDonald 2010 criteria and 5/49
(10%) the McDonald 2017 criteria (gain of 1 patient due to
OCBs). None of the patients fulﬁlled the criteria for CDMS
during FU.
Discussion
We investigated the application of the novel McDonald 2017
criteria for pediatric MS in clinical practice. We show that the
McDonald 2017 criteria have a higher sensitivity than the
previous 2010 criteria for CDMS diagnosis for pediatric
patients (83% vs 49%, p < 0.001). However, the speciﬁcity was
lower (73% vs 87%, p = 0.02). Overall, the diagnostic accuracy
Table 4 Hazard ratios for CDMS diagnosis after applying DIS, DIT, and full criteria (DIS + DIT) forMcDonald 2010 and 2017
on baseline MRI
McDonald 2010 p Value McDonald 2017 p Value
DIS (n=110) HR 5.8 (95% CI 3.0–11.4) p < 0.001 HR 11.3 (95% CI 4.0–31.6) p < 0.001
DIT (n=93) HR 2.9 (95% CI 1.5–5.4) p = 0.001 HR 8.3 (95% CI 3.0–23.4) p < 0.001
DIS + DIT (n=93) HR 3.1 (95% CI 1.7–5.8) p < 0.001 HR 8.5 (95% CI 3.5–20.4) p < 0.001
Abbreviations: CDMS = clinically definite MS; DIS = dissemination in space; DIT = dissemination in time; HR = hazard ratio.
Figure 2 Time from incident ADS event to MS diagnosis
Survival curves for time from incident ADS event to MS diagnosis according
to the McDonald 2010 criteria (at baseline), McDonald 2017 criteria (at
baseline), and CDMS. ADS = acquired demyelinating syndrome; CDMS =
clinically definite multiple sclerosis.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 2 | March 2019 7
of the 2017 criteria was higher than that for the 2010 criteria
(77% vs 70%). The revised criteria are easier to apply than the
McDonald 2010 criteria, mainly because of the major change
of accepting all lesions to contribute to DIS and DIT, without
taking the clinical symptoms into account. Moreover, we
show that the 2017 McDonald criteria lead to more MS di-
agnosis at baseline; therefore, MS diagnosis can be made
earlier using the 2017 criteria.
A high sensitivity is important to start DMT as soon as pos-
sible,26 which might lead to overtreatment in the group of
patients who have a less active clinical disease course. Our main
ﬁndings are supported by a recent extensive study in a cohort of
patients with ADS that also included evaluation of the appli-
cability of the McDonald 2017 criteria.15 We validate their
ﬁnding that the sensitivity is increased and speciﬁcity is de-
creased mainly by including OCB status into the 2017 criteria.
However, the speciﬁcity of the McDonald 2017 criteria in our
study is somewhat lower. This is probably due to our study
design by taking CDMS, a more clinical primary endpoint
instead of new T2 lesions on a second MRI. We identiﬁed
a minor subgroup of 7 patients who were responsible for the
loss in speciﬁcity andwho had an FUduration of 2.3 years. New
lesions on subsequent MRI were observed in 4 of these
patients. The other 3 patients did not undergo a second MRI.
However, given the presence of typical MS lesions at baseline
and OCB positivity in these 3 patients, it is quite likely that
these patients would also have developed newMRI lesions after
a longer FU. Taken together, we believe that initiation of DMT
based on the novel criteria is warranted. Yet, clinicians should
be aware that with the McDonald 2017 criteria, more patients
will be identiﬁed at baseline and that a proportion of these
patients will clinically have a less active disease course.
Performing spinal MRI led to fulﬁllment of the McDonald
2017 criteria at baseline in 3/41 (7%) patients with CDMS,
but did not have additional value in the McDonald 2010
criteria, in line with another study that indicated limited value
of spinal cord imaging in the McDonald 2010 criteria in
children.6 Fadda et al.15 argued whether spinal cord acquisi-
tion would meaningfully add to the performance of the
McDonald 2017 criteria because only a real small proportion
of their patients fulﬁlled the criteria based on spinal cordMRI.
However, in our cohort, 7% of the patients with CDMS could
have been identiﬁed at baseline, which could signiﬁcantly
reduce the time to diagnosis in these patients. The exact place
of spinal cord imaging as part of the MS diagnostic procedure
deserves further investigation.
Our data show that approximately 10% of the patients with
ADEM fulﬁll the McDonald 2010 and 2017 criteria at base-
line. However, no patient with ADEM was diagnosed with
CDMS in our cohort. The IPMSSG 2012 criteria explicitly
mention not to apply the McDonald 2010 criteria to patients
with ADEM. Our data support this view for the McDonald
2017 criteria to prevent the incorrect initiation of treatment in
these monophasic patients.
Regarding age, ADS– patients aged <12 years seemed to have
better accuracy for the McDonald 2017 criteria than the total
group (sensitivity 100% vs 90%, speciﬁcity 81% vs 60%, PPV
both 64%, NPV 100% vs 89%), despite the small sample size
for this analysis. This implies that both the McDonald 2010
criteria andMcDonald 2017 criteria can be used across the age
span, including children aged <12 years with ADS, excluding
patients with ADEM, in keeping with the results from pre-
vious studies.12,15,27
Our study has several limitations. The choice of brain and/or
spinal MRI, inclusion of contrast or not, and the decision to
include testing for CSF OSBs were left to the discretion of the
treating physician. For example, spinal imaging is not always
justiﬁed (sedation may be needed), CSF is not always tested
in isolated optic neuritis, and a paired serum sample is not
always available with CSF (e.g., in the case of exclusion of
suspected infection). Therefore, similar to other studies on
the diagnostic criteria for pediatric MS, there was not com-
plete coverage of all potentially relevant parameters. How-
ever, our main goal was to evaluate the revised 2017 criteria in
real-world data; therefore, we did not exclude patients from
the analyses. Instead, a few subanalyses have been performed.
Despite our considerable FU duration of median 4.6 years, it
is possible that some patients may develop a second attack in
the future. DMT could have postponed CDMS diagnosis;
however, our subanalysis excluding these patients showed no
diﬀerences in test characteristics. Second, the PROUD-kids
study did not have a standardized MRI FU; therefore, we did
not take FU MRIs into account for the analysis of the 2010
and 2017 criteria. However, the scope of this article was to
analyze the diagnostic accuracy for CDMS at the ﬁrst attack
of ADS.
Our data suggest that the McDonald 2017 criteria perform
well in children. MS diagnosis can bemade earlier and leads to
a higher number of patients with MS at baseline. Both the
McDonald 2010 and 2017 criteria show similar results for the
patients aged <12 years presenting with ADS and can there-
fore be applied in this population as well. As proposed by the
IPMSSG for the McDonald 2010 criteria, application of both
2010 and 2017 criteria in patients with ADEM should be
avoided.
Acknowledgment
The authors thank all the children and their families who
participated in the Dutch PROUD-kids study for acquired
demyelinating syndromes in children.
Study funding
The study was supported by the Dutch MS Research Foun-
dation. This study was not industry sponsored.
Disclosure
Y.Y.M. Wong, C.L. de Mol, R.M. van der Vuurst de Vries, E.D.
van Pelt, and I.A. Ketelslegers report no disclosures. C.E.
Catsman-Berrevoets received travel funding from the European
8 Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 2 | March 2019 Neurology.org/NN
Paediatric Neurology Society. R.F. Neuteboom served on the
scientiﬁc advisory board of LAREB and data safety monitory
board of the EXCEL study. R.Q. Hintzen participated in trials
with Biogen Idec, Merck Serono, Roche, and Novartis and is on
the editorial board of Multiple Sclerosis and Related Disorders.
Full disclosure form information provided by the authors is
available with the full text of this article at Neurology.org/NN.
Publication history
Received by Neurology: Neuroimmunology & Neuroinﬂammation August
20, 2018. Accepted in ﬁnal form October 23, 2018.
References
1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502–1517.
2. Venkateswaran S, Banwell B. Pediatric multiple sclerosis. Neurologist 2010;16:
92–105.
3. Waldman A, Ghezzi A, Bar-Or A, Mikaeloﬀ Y, Tardieu M, Banwell B. Multiple
sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and re-
search. Lancet Neurol 2014;13:936–948.
4. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis:
2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
5. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017
revisions of the McDonald criteria. Lancet Neurol 2018;17:162–173.
6. Hummel HM, Bruck W, Dreha-Kulaczewski S, Gartner J, Wuerfel J. Pediatric onset
multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI.
Mult Scler 2013;19:1330–1335.
7. Kornek B, Schmitl B, Vass K, et al. Evaluation of the 2010 McDonald multiple
sclerosis criteria in children with a clinically isolated syndrome. Mult Scler 2012;18:
1768–1774.
8. Sadaka Y, Verhey LH, Shroﬀ MM, et al. McDonald criteria for diagnosing pediatric
multiple sclerosis. Ann Neurol 2012;72:211–223.
9. Sedani S, Lim MJ, Hemingway C, Wassmer E, Absoud M. Paediatric multiple
sclerosis: examining utility of the McDonald 2010 criteria. Mult Scler 2012;18:
679–682.
10. Tantsis EM, Prelog K, Brilot F, Dale RC. Risk of multiple sclerosis after a ﬁrst
demyelinating syndrome in an Australian Paediatric cohort: clinical, radiological
features and application of the McDonald 2010 MRI criteria. Mult Scler 2013;19:
1749–1759.
11. Williams MT, Tapos DO, Juhasz C. Use of the 2010 McDonald criteria can facilitate
early diagnosis of pediatric multiple sclerosis in a predominantly black cohort. Pediatr
Neurol 2014;51:826–830.
12. van Pelt ED, Neuteboom RF, Ketelslegers IA, Boon M, Catsman-Berrevoets CE,
Hintzen RQ. Application of the 2012 revised diagnostic deﬁnitions for paediatric
multiple sclerosis and immune-mediated central nervous system demyelination dis-
orders. J Neurol Neurosurg Psychiatry 2014;85:790–794.
13. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis
Study group criteria for pediatric multiple sclerosis and immune-mediated central
nervous system demyelinating disorders: revisions to the 2007 deﬁnitions. Mult Scler
2013;19:1261–1267.
14. Hintzen RQ, Dale RC, Neuteboom RF, Mar S, Banwell B. Pediatric acquired CNS
demyelinating syndromes: features associated with multiple sclerosis. Neurology
2016;87:S67–S73.
15. Fadda G, Brown RA, Longoni G, et al. MRI and laboratory features and the performance
of international criteria in the diagnosis of multiple sclerosis in children and adolescents:
a prospective cohort study. Lancet Child Adolesc Health 2018;2:191–204.
16. de Mol CL, Wong YYM, van Pelt ED, et al. Incidence and outcome of acquired
demyelinating syndromes in Dutch children: update of a nationwide and prospective
study. J Neurol 2018;265:1310–1319.
17. Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, et al. Incidence of acquired
demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol
2012;259:1929–1935.
18. van der Vuurst de Vries RM, van Pelt ED, Mescheriakova JY, et al. Disease course after
clinically isolated syndrome in children versus adults: a prospective cohort study. Eur J
Neurol 2017;24:315–321.
19. Dale RC, Brilot F, Banwell B. Pediatric central nervous system inﬂammatory
demyelination: acute disseminated encephalomyelitis, clinically isolated syn-
dromes, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2009;22:
233–240.
20. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic deter-
minants of multiple sclerosis in children with acute demyelination: a prospective
national cohort study. Lancet Neurol 2011;10:436–445.
21. Mikaeloﬀ Y, Suissa S, Valle´e L, et al. First episode of acute CNS inﬂammatory
demyelination in childhood: prognostic factors for multiple sclerosis and disability.
J Pediatr 2004;144:246–252.
22. Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in
children with relapsing myelin oligodendrocyte glycoprotein antibody-associated
disease. JAMA Neurol 2018;75:478–487.
23. Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG anti-
bodies in children with an acquired demyelinating syndrome. Neurology 2017;89:
900–908.
24. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy
in multiple sclerosis: report by the panel on the evaluation of experimental trials of
therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552–568.
25. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of
cerebrospinal ﬂuid analysis in the diagnosis of multiple sclerosis: a consensus state-
ment. Arch Neurol 2005;62:865–870.
26. Ghezzi A, Amato MP, Makhani N, Shreiner T, Ga¨rtner J, Tenembaum S. Pediatric
multiple sclerosis: conventional ﬁrst-line treatment and general management. Neu-
rology 2016;87:S97–S102.
27. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired
demyelinating syndromes in children. Neurology 2017;89:269–278.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 2 | March 2019 9
Appendix 1 Author contributions
Name Degrees Location Role Contribution
Yu Yi M. Wong MD Department of Neurology, MS Centre
ErasMS, Erasmus MC, Rotterdam, The
Netherlands
First author Study design, acquisition of data, statistical analysis,
interpretation of data, and drafting of the
manuscript
C. Louk de Mol BSc Department of Neurology, MS Centre
ErasMS, Erasmus MC, Rotterdam, The
Netherlands
Coauthor Study design, acquisition of data, statistical analysis,
interpretation of data, and drafting of manuscript
RoosM. van der Vuurst
de Vries
MD Department of Neurology, MS Centre
ErasMS, Erasmus MC, Rotterdam, The
Netherlands
Coauthor Interpretation of data and revision of themanuscript
for content
E. Danie¨lle van Pelt MD, PhD Department of Neurology, MS Centre
ErasMS, Erasmus MC, Rotterdam, The
Netherlands
Co-author Acquisition of data and revision of the manuscript
for content
Immy A. Ketelslegers MD, PhD Department of Neurology, MS Centre
ErasMS, Erasmus MC, Rotterdam, The
Netherlands
Coauthor Acquisition of data and revision of the manuscript
for content
Coriene E. Catsman-
Berrevoets
MD, PhD Department of Pediatric Neurology,
Erasmus MC, Rotterdam, The
Netherlands
Coauthor Acquisition of data, revision of manuscript for
content
Rinze F. Neuteboom MD, PhD Department of Pediatric Neurology,
Erasmus MC, Rotterdam, The
Netherlands
Last author Study design, study supervision, acquisition of data,
interpretation of data, and revision of the
manuscript for content
Rogier Q. Hintzen MD, PhD Department of Neurology, MS Centre
ErasMS, Erasmus MC, Rotterdam, The
Netherlands
Last author,
corresponding
author
Study design, study supervision, interpretation of
data, and revision of the manuscript for content
10 Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 2 | March 2019 Neurology.org/NN
Appendix 2 Coinvestigators
Name Degrees Location Role Contribution
D.P. Bakker MD, PhD Departments of Pediatric Neurology, VU Medical Centre,
Amsterdam
Coinvestigator Collection of data
M. Boon MD, PhD Department of Pediatric Neurology, UMCG, Groningen Coinvestigator Collection of data
K.P.J. Braun MD, PhD Department of Pediatric Neurology, University Medical
Centre Utrecht, Utrecht
Coinvestigator Collection of data
K.G.J. van Dijk MD, PhD Department of Pediatrics, Rijnstate Hospital, Arnhem Coinvestigator Collection of data
M.J. Eikelenboom MD, PhD Department of Neurology, Westfriesgasthuis, Hoorn Coinvestigator Collection of data
M. Engelen MD, PhD Department of Pediatric Neurology, Academic Medical
Centre Amsterdam, Amsterdam
Coinvestigator Collection of data
K. Geleijns MD, PhD Department of Pediatric Neurology, University Medical
Centre Utrecht, Utrecht
Coinvestigator Collection of data
C.A. Haaxma MD, PhD Department of Pediatric Neurology, Radboud UMC,
Nijmegen
Coinvestigator Collection of data
J.M.F. Niermeijer MD, PhD Department of Neurology, Elisabeth-Tweesteden
Hospital, Tilburg
Coinvestigator Collection of data
E.H. Niks MD, PhD Department of Neurology, Leiden University Medical
Centre, Leiden
Coinvestigator Collection of data
C.M.P.C.D. Peeters-Scholte MD, PhD Department of Neurology, Leiden University Medical
centre, Leiden
Coinvestigator Collection of data
E.A.J. Peeters MD, PhD Department of Neuropediatrics, Haga Hospital, the
Hague
Coinvestigator Collection of data
B.T. Poll MD, PhD The Department of Pediatric Neurology, Emma
Children’s Hospital/AMC, Amsterdam
Coinvestigator Collection of data
R.P. Portier MD Department of Neurology, Medisch Spectrum Twente,
Enschede
Coinvestigator Collection of data
J.F. de Rijk-van Andel MD, PhD Department of Neurology, Amphia Hospital, Breda Coinvestigator Collection of data
J.P.A. Samijn MD, PhD Department of Neurology, Maasstad Hospital,
Rotterdam
Coinvestigator Collection of data
H.M. Schippers MD Department of Neurology, St. Antonius Hospital,
Nieuwegein
Coinvestigator Collection of data
I.N. Snoeck MD Department of Neuropediatrics, Haga Hospital, the
Hague
Coinvestigator Collection of data
H. Stroink MD, PhD Department of Neurology, Canisius-Wilhelmina Hospital,
Nijmegen
Coinvestigator Collection of data
R.J. Vermeulen MD, PhD Department of Pediatric Neurology, Maastricht UMC,
Maastricht
Coinvestigator Collection of data
A. Verrips MD, PhD Department of Neurology, Canisius-Wilhelmina Hospital,
Nijmegen
Coinvestigator Collection of data
F. Visscher MD Department of Pediatric Neurology, Admiraal de Ruyter
Hospital, Goes
Coinvestigator Collection of data
J.H.S. Vles MD, PhD Department of Pediatric Neurology, Maastricht UMC,
Maastricht
Coinvestigator Collection of data
M.A.A.P. Willemsen MD, PhD Department of Pediatric Neurology, Radboud UMC,
Nijmegen
Coinvestigator Collection of data
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 2 | March 2019 11
DOI 10.1212/NXI.0000000000000528
2019;6; Neurol Neuroimmunol Neuroinflamm 
Yu Yi M. Wong, C. Louk de Mol, Roos M. van der Vuurst de Vries, et al. 
Real-world validation of the 2017 McDonald criteria for pediatric MS
This information is current as of December 17, 2018
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
Services
Updated Information &
 http://nn.neurology.org/content/6/2/e528.full.html
including high resolution figures, can be found at:
References
 http://nn.neurology.org/content/6/2/e528.full.html##ref-list-1
This article cites 27 articles, 1 of which you can access for free at: 
Citations
 http://nn.neurology.org/content/6/2/e528.full.html##otherarticles
This article has been cited by 1 HighWire-hosted articles: 
Subspecialty Collections
 http://nn.neurology.org//cgi/collection/multiple_sclerosis
Multiple sclerosis
 http://nn.neurology.org//cgi/collection/mri
MRI
 http://nn.neurology.org//cgi/collection/all_pediatric
All Pediatric
 http://nn.neurology.org//cgi/collection/all_demyelinating_disease_cns
All Demyelinating disease (CNS)
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://nn.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://nn.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
